Accéder au contenu
Merck

Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus.

Gastroenterology (2014-03-04)
Yijin Wang, Xinying Zhou, Yannick Debing, Kan Chen, Luc J W Van Der Laan, Johan Neyts, Harry L A Janssen, Herold J Metselaar, Maikel P Peppelenbosch, Qiuwei Pan
RÉSUMÉ

Many recipients of organ transplants develop chronic hepatitis, due to infection with the hepatitis E virus (HEV). Although chronic HEV infection is generally associated with immunosuppressive therapies, little is known about how different immunosuppressants affect HEV infection. A subgenomic HEV replication model, in which expression of a luciferase reporter gene is measured, and a full-length infection model were used. We studied the effects of different immunosuppressants, including steroids, calcineurin inhibitors (tacrolimus [FK506] and cyclosporin A), and mycophenolic acid (MPA, an inhibitor of inosine monophosphate dehydrogenase) on HEV replication in human hepatoma cell line Huh7. Expression of cyclophilins A and B (the targets of cyclosporin A) were knocked down using small hairpin RNAs. Steroids had no significant effect on HEV replication. Cyclosporin A promoted replication of HEV in the subgenomic and infectious models. Knockdown of cyclophilin A and B increased levels of HEV genomic RNA by 4.0- ± 0.6-fold and 7.2- ± 1.9-fold, respectively (n = 6; P < .05). A high dose of FK506 promoted infection of liver cells with HEV. In contrast, MPA inhibited HEV replication. Incubation of cells with guanosine blocked the antiviral activity of MPA, indicating that the antiviral effects of this drug involve nucleotide depletion. The combination of MPA and ribavirin had a greater ability to inhibit HEV replication than MPA or ribavirin alone. Cyclophilins A and B inhibit replication of HEV; this might explain the ability of cyclosporin A to promote HEV infection. On the other hand, the immunosuppressant MPA inhibits HEV replication. These findings should be considered when physicians select immunosuppressive therapies for recipients of organ transplants who are infected with HEV.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Dexaméthasone, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Dexaméthasone, ≥98% (HPLC), powder
USP
Tacrolimus, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Potassium, chunks (in mineral oil), 98% trace metals basis
Sigma-Aldrich
Prednisolone, ≥99%
Sigma-Aldrich
Potassium hydride, 30 wt % dispersion in mineral oil
Sigma-Aldrich
Dexaméthasone, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
USP
Dexaméthasone, United States Pharmacopeia (USP) Reference Standard
Supelco
Dexaméthasone, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
FK-506 monohydrate, ≥98% (HPLC)
Sigma-Aldrich
Potassium hydride, in paraffin
Supelco
Prednisolone, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Prednisolone, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Dexaméthasone, meets USP testing specifications
Sigma-Aldrich
Dexaméthasone, tested according to Ph. Eur.
Prednisolone, European Pharmacopoeia (EP) Reference Standard
Supelco
Dexaméthasone, VETRANAL®, analytical standard
Supelco
Prednisolone, VETRANAL®, analytical standard
Dexaméthasone, European Pharmacopoeia (EP) Reference Standard
Dexaméthasone, European Pharmacopoeia (EP) Reference Standard
Prednisolone for peak identification, European Pharmacopoeia (EP) Reference Standard
Prednisolone, British Pharmacopoeia (BP) Assay Standard
Dexaméthasone, British Pharmacopoeia (BP) Assay Standard
Prednisolone for system suitability, European Pharmacopoeia (EP) Reference Standard
Dexaméthasone, European Pharmacopoeia (EP) Reference Standard